Ultragenyx Pharmaceutical Inc. financial data

Symbol
RARE on Nasdaq
Location
60 Leveroni Court, Novato, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 227 % -20.5%
Quick Ratio 15 % +5.66%
Debt-to-equity 844 % +112%
Return On Equity -414 % -121%
Return On Assets -43.7 % -16.3%
Operating Margin -86.3 % +15.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96.5M shares +4.48%
Common Stock, Shares, Outstanding 96.4M shares +4.48%
Entity Public Float 3.7B USD +19.4%
Common Stock, Value, Issued 96K USD +4.35%
Weighted Average Number of Shares Outstanding, Basic 99.8M shares +4.48%
Weighted Average Number of Shares Outstanding, Diluted 99.8M shares +4.48%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 631M USD +20.6%
Research and Development Expense 734M USD +9.52%
Operating Income (Loss) -544M USD -1.54%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -577M USD -2.79%
Income Tax Expense (Benefit) 3.11M USD +188%
Net Income (Loss) Attributable to Parent -580M USD -3.73%
Earnings Per Share, Basic -5 USD/shares +7.83%
Earnings Per Share, Diluted -5 USD/shares +7.83%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 203M USD +34.5%
Accounts Receivable, after Allowance for Credit Loss, Current 113M USD +20.6%
Inventory, Net 52.2M USD +20.5%
Other Assets, Current 41.4M USD
Assets, Current 643M USD -19.6%
Property, Plant and Equipment, Net 250M USD -8.25%
Operating Lease, Right-of-Use Asset 25.5M USD +6.7%
Intangible Assets, Net (Excluding Goodwill) 173M USD +4.85%
Goodwill 44.4M USD 0%
Other Assets, Noncurrent 57.9M USD +7.4%
Assets 1.19B USD -22.6%
Accounts Payable, Current 40.6M USD +12.7%
Employee-related Liabilities, Current 84.4M USD +1.77%
Accrued Liabilities, Current 221M USD +19.2%
Liabilities, Current 340M USD +19.3%
Deferred Income Tax Liabilities, Net 30.1M USD 0%
Operating Lease, Liability, Noncurrent 21.7M USD
Other Liabilities, Noncurrent 18.8M USD +16.5%
Liabilities 1.17B USD -0.87%
Accumulated Other Comprehensive Income (Loss), Net of Tax 820K USD -8.48%
Retained Earnings (Accumulated Deficit) -4.4B USD -15.2%
Stockholders' Equity Attributable to Parent 9.16M USD -97.4%
Liabilities and Equity 1.19B USD -22.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -166M USD +12.7%
Net Cash Provided by (Used in) Financing Activities 157M USD
Net Cash Provided by (Used in) Investing Activities 120M USD +27%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 72.2M shares +2.99%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -45M USD +53.6%
Deferred Tax Assets, Valuation Allowance 1.21B USD +16.5%
Deferred Tax Assets, Gross 1.21B USD +16.5%
Operating Lease, Liability 40.3M USD -6.56%
Payments to Acquire Property, Plant, and Equipment 1.32M USD -58.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -580M USD -4.33%
Lessee, Operating Lease, Liability, to be Paid 49.6M USD -8.82%
Property, Plant and Equipment, Gross 378M USD +1.19%
Operating Lease, Liability, Current 12.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.9M USD +16.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 13.8M USD -14.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +10.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.23M USD -17.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.02M USD +6.99%
Deferred Tax Assets, Operating Loss Carryforwards 309M USD +16.2%
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 97M USD +21.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.71M USD +14.4%
Additional Paid in Capital 4.41B USD +5.81%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 8.99M USD +1.64%
Deferred Tax Assets, Net of Valuation Allowance 7.15M USD +20%
Share-based Payment Arrangement, Expense 156M USD +2.71%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%